EP2027465A2 - Procédé d'analyse automatique des tissus - Google Patents

Procédé d'analyse automatique des tissus

Info

Publication number
EP2027465A2
EP2027465A2 EP07777137A EP07777137A EP2027465A2 EP 2027465 A2 EP2027465 A2 EP 2027465A2 EP 07777137 A EP07777137 A EP 07777137A EP 07777137 A EP07777137 A EP 07777137A EP 2027465 A2 EP2027465 A2 EP 2027465A2
Authority
EP
European Patent Office
Prior art keywords
fluorescently labeled
cellular systems
systems biology
data
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07777137A
Other languages
German (de)
English (en)
Inventor
Albert H. Gough
Kenneth A. Giuliano
D. Lansing Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellumen Inc
Original Assignee
Cellumen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellumen Inc filed Critical Cellumen Inc
Publication of EP2027465A2 publication Critical patent/EP2027465A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/6456—Spatial resolved fluorescence measurements; Imaging
    • G01N21/6458—Fluorescence microscopy
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/10—Image acquisition modality
    • G06T2207/10056—Microscopic image
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays

Definitions

  • HCS High content screening
  • multiparameter HCS technologies were developed to automate cell analysis for drug discovery, HCS technologies are focused specifically on the measurement of individual targets or pathways in arrays of cultured cells treated with test compounds.
  • HCS tools alone do not address the complete workflow of tissue based cellular systems biology.
  • the cell is the simplest living system. Tissues are collections of specific cell types forming interacting colonies of cells. Although cells and tissues are less complex than a complete organism, they possess significant functional complexity allowing a detailed understanding of many aspects affecting a whole organism, such as the cellular basis of disease, treatment efficacy and potential toxicity of treatments. Multicolor fluorescence of multiplexed biomarkers coupled with searchable databases provides the basis for cellular systems biology (also referred to herein as systems cell biology) profiling and analysis. This invention provides for methods of analyzing and profiling, the analysis of, and means for profiling, tissue-based cellular systems biology.
  • the cellular systems biology approach including the combining of traditional histological staining with fluorescent staining to associate cellular and tissue markers that can be labeled by fluorescence has not been previously applied by others as now described herein.
  • the use of the transmitted light images based on traditional histological stains used by pathologist as a "reference" image or "map" for better interpretation of the multiple fluorescence-based reagents as described herein will increase the acceptance of the systems approach by pathologists and will allow selection of a particular set of biomarkers for fluorescence analysis.
  • a method for producing a cellular systems biology profile of one or more tissue samples is provided.
  • cellular systems biology is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions.
  • a cellular systems biology profile is a systemic characterization of cells in the context of a tissue architecture such that the cells have particular characteristics dependent upon the relationships of different cells within a tissue and the biological or medical state of the tissue. It is the interactions, relationships, and state of the constituents of cells within a tissue that gives rise to the cellular systems biology features that are used to construct a profile.
  • a cellular systems biology profile defines the interrelationships between a combination of at least five cellular systems biology features collected from cells within one or more tissue sections from the same sample.
  • the invention is directed to a method for producing one or more cellular systems biology profiles for one or more tissue samples, comprising obtaining at least two sections from one or more tissue samples. At least one section is labeled with a histological stain, to produce a histologically stained section. At least one other section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. In some embodiments the histologically stained section and the fluorescently stained section are the same or different, hi a particular embodiment, the histologically stained section and the fluorescently stained section are different section. Each fluorescently labeled reagent is specific for a biomarker.
  • a biomarker is a molecule which provides a measure of cellular and/or tissue function.
  • a biomarker can be the measure of estrogen receptor expression levels, Her2/neu expression, transcription factor activation, location or amount or activity of a protein, polynucleotide, organelle, and the like, the phosphorylation status of a protein, etc.
  • the panel of fluorescently labeled reagents detects at least about four different biomarkers.
  • a biomarker in one or more sections is a read-out of one or more features of the tissue.
  • a “feature” is a characteristic which provides a measurement or series of measurements of a particular biomarker (which can indicate a biological function) made in time and/or space within cells and tissues.
  • Bio functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non-coding RNAs and proteins, morphology, state of differentiation, and the like.
  • a single biomarker can provide a read-out of more than one feature.
  • Hoechst dye can be used to detect DNA (e.g., a biomarker), and a number of features of the tissue (e.g., nucleus size, cell cycle stage, number of nuclei, presence of apoptotic nuclei, etc.) can be identified by the DNA detected with the Hoechst dye.
  • the method further comprises imaging the histologically stained section using a first optical mode, which produces a first set of data and imaging the fluorescently labeled section using a second optical mode, which produces a second set of data.
  • the first set of data and the second set of data are analyzed to identify five or more features, such that at least one feature is identified in each of the first set of data and the second set of data.
  • the combination of the five or more features generates a cellular systems biology profile of the one or more tissue samples.
  • the cellular systems biology profile is stored in a database for reference, thereby providing a reference cellular systems biology profile in a database.
  • the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples
  • the method for producing a cellular systems biology profile of one or more tissue samples comprises obtaining at least one section from one or more tissue samples. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section, such that each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method further comprises imaging the fluorescently labeled section with at least a first optical mode to produce a first set of data which is analyzed to identify at least about five or more features, wherein at least one feature is identified in the first set of data, and wherein the combination of the five or more features is a cellular systems biology profile the one or more tissue samples.
  • the method produces a cellular systems biology profile of the one or more tissue samples.
  • the method can further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
  • a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer.
  • different cancers can be classified and staged according to their pathology.
  • the method described herein permits, for example, the confirmation of the presence or absence of a cancer, the identification of a cancer, the classification of a cancer stage, the prediction and/or determination of the outcome or prognosis of the cancer, and the response of the cancer to any treatments.
  • the method comprises obtaining at least two sections from one or more tissue samples.
  • At least one section is labeled with a histological stain to produce a histologically stained section. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents comprises fluorescently labeled reagents which can be selected from the group consisting of: i) one or more fluorescently labeled reagents specific for at least four cancer cell biomarkers; ii) one or more fluorescently labeled reagents specific for at least four migratory immune cell biomarkers; iii) a combination of A) one or more fluorescently labeled reagents specific for at least three cancer cell biomarkers and B) one or more fluorescently labeled reagents specific for at least three migratory immune cell biomarkers, and iv) combinations of the above, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers.
  • the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method further comprises imaging the histologically stained section with at least a first optical mode to produce a first set of data and imaging the fluorescently labeled section with at least a second optical mode to produce a second set of data.
  • the first set of data and second set of data are analyzed to identify at least about five or more features, such that at least one feature is identified in each of the first set of data and the second set of data.
  • the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples, and thus the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or the absence of a cancer.
  • the one or more tissue samples is selected from the group consisting a suspected or known cancerous tissue, a lymph node, and a combination thereof.
  • the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples
  • a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
  • the method comprises obtaining at least two sections from one or more tissue samples. At least one section labeled with a histological stain to produce a histologically stained section and at least one section is with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents comprises a set of fluorescently labeled reagents selected from the group consisting of i) one or more fluorescently labeled reagents specific for cell metabolism biomarkers, ii) one or more fluorescently labeled reagents specific for DNA damage biomarkers, iii) one or more fluorescently labeled reagents specific for cell morphology biomarkers, iv) one or more fluorescently labeled reagents specific for DNA damage biomarkers, v) one or more fluorescently labeled reagents specific for cell differentiation biomarkers, vi) one or more fluorescently labeled reagents specific for stress-induced transcription activation or inhibition biomarkers, vii) a one or more fluorescently labeled reagents specific for phosphorylation status of stress kinase biomarkers, viii) one or more fluorescently labeled reagents specific for apoptosis or necrosis biomarkers, ix) one or
  • the histologically stained section is imaged with at least a first optical mode to produce a first set of data.
  • the fluorescently labeled section is imaged with at least a second optical mode to produce a second set of data.
  • the method further comprises analyzing the first set of data and second set of data to identify at least about five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data.
  • the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples.
  • the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
  • the one or more tissue samples is one or more liver tissue samples.
  • FIG. 1 are examples of slides for Tissue Profiling.
  • FIG. IA is Sample #01, which represents a slide that combines a tissue section labeled with H&E stain, and a sequential section labeled with fluorescent tags for specific biomarkers.
  • FIG. IB is Sample #02, which illustrates a slide with an H&E stained section, a fluorescent labeled section and some cells isolated from patient tissue and labeled with fluorescent tags (pictures of sections and cells are all enlarged for illustrative purposes).
  • FIG. 2 is a schematic of systems cell biology (also referred to herein as cellular systems biology) profiling, which involves the analysis of a diverse set of cellular biomarkers used to identify features to create a profile.
  • FIG. 2A represent cells from a patient that are, e.g., healthy, diseased or being treated or have been treated with a drug.
  • FIG. 2B schematically represents the analysis of a set of biomarkers.
  • FIG. 2C represents a panel of cellular biomarkers used to produce cellular systems biology profile. These profiles are stored in a database (schematically shown in FIG. 2D), which can be used a reference database. Comparison of a patient profile with reference profiles is used e.g., as a predictive tool, or to associate a biomarker, feature or a profile with a specific medical condition, or to evaluate new profiles.
  • FIG. 2D can be used a reference database. Comparison of a patient profile with reference profiles. Comparison of a patient profile with reference profiles is used e.g., as a predictive tool, or to associate a biomarker, feature or a profile with a specific medical condition, or to evaluate new profiles.
  • FIG. 3 is a schematic illustrating the interrelation of systems cell biology which captures enough complexity to correlate biomarkers with higher level organ and organism effects, while allowing high throughput and cost-effective profiling.
  • Cellular systems biology and systems biology are based on the interactions and relationships between the fundamental components of living systems represented by the "-omics" and a selection of specific cellular biomarkers are obtained from a combination of genomics, proteomics and metabolomics, in the context of the cells studied (cellomics).
  • FIG. 4 is a schematic of how a cell integrates the many processes illustrated, such as gene expression, energy metabolism, etc. to yield normal functions. Diseases result from the dysregulation of one or more of these cellular processes which often results in complex symptoms. Many of these processes share pathways, signals and proteins and therefore should be investigated as part of the cell system (including the collection of cells of different types in tissues).
  • FIG. 5 illustrate examples of biomarkers for use in patient tissue profiling selected from function classes that include, for example: (A) Stress Pathways; (B) Organelle Function; (C) Cell Cycle; (D) Morphology; (E) Apoptosis; and (F) DNA Damage, as well as micro RNA, and migratory immune cells. Specific combinations of biomarkers are selected for analysis of particular disease conditions, as described herein.
  • FIG. 6 is an example of the multiplexed labeling of cells with a panel of biomarkers such as would be used in tissue sections. Labels are multiplexed in tissue which allows analysis of correlations between biomarker activation within the same tissue, and to reduce the number of sections that must be prepared and analyzed. In a particular embodiment, at least four or more biomarkers are analyzed in each section.
  • FIG. 7 is a schematic flow chart of the process of creating a reference profile database as described in one embodiment of the invention.
  • Box 1 Sequential tissue sections are prepared and mounted.
  • Box 2(a) One section is labeled with H&E stain for transmitted light imaging or review.
  • Box 2(b) A second section is labeled with a panel of fluorescent labels to measure biomarkers.
  • Boxes 3(a & b) Sections are imaged or viewed for interpretation.
  • Boxes 4(a & b) Sections are analyzed and/or interpreted to create data.
  • Box 5 Data from the sequential sections are compared and combined.
  • Box 6 The cellular systems profile is added to database.
  • Box 7 Tissue profiles in database are clustered to identify similarities.
  • Box 8 Profile classes are identified.
  • Box 9 Correlations between systems profiles and histological data are used to build a classifier which is stored in the database.
  • FIG. 8 is a flow chart illustrating the process of analyzing and classifying tissue,
  • FIGS. 9A-I is a flow chart illustrating the overall process for automated tissue profiling in one embodiment of the invention.
  • FIG. 9(A) Process starts with reference tissue with know medical history.
  • FIG. 9(B) Profiles from fluorescence analysis are combined with results from human interpretation of stained sections along with medical history;
  • FIG. 9(D) populate a reference database.
  • FIG. 9(E) Patient tissues are FIG. 9(F) prepared, analyzed and FIG. 9(G) classified to identify FIG. 9(H) similarities to other patient profiles (patient stratification) and FIG. 9(1) to make predictions regarding medical conditions, or medical outcomes.
  • FIG. 10 is a flow chart of the process for selecting biomarkers for a cancer tissue profiling panel.
  • Box (1) Normal tissue from Patient is (Box 2) analyzed by Gene Expression profiling.
  • Box (3) A sample of tumor tissue from the same patient is (Box 4) analyzed by Gene Expression Profiling and is (Box 5) staged in the traditional manner. This combined information, comparing "normal" tissue with patient tumor tissue is (Box 6) used to identify potential biomarkers.
  • Box (7) Gene products are prioritized based on known reference points including Her2/Neu and then antibodies acquired or produced to create test panels (Box 8).
  • the design of the biomarker panel is based on the selection of combinations of cancer cell biomarkers that are multiplexed for fluorescence-based immunohistochernistry (IHC).
  • IHC fluorescence-based immunohistochernistry
  • FIG. 11 is an overview of one embodiment of the invention.
  • Tissue samples from a patient which could include healthy tissue, tumor tissue, other diseased tissue or a blood specimen are processed by standard methods for mounting on slides (B) either as individual sections or as tissue microarrays. Slides are imaged on a microscope or other imaging system (C). Images are interpreted either by a pathologist or through the application of image analysis algorithms to produce data (D) which can be stored in a database. The combination of the data from a single specimen forms a cellular systems profile of that specimen.
  • Data from multiple cellular systems profiles are analyzed using statistical methods including cluster analysis, principle component analysis, and other multifactorial methods to identify similarities between profiles which can be represented in a clustered heat map (E), identify patterns within a profile that indicate a certain biological or medical state, and to classify tissue status based on similarity in profiles.
  • the information provided by cellular systems biology profiling is used by the physician or scientist (F) to better understand the biology or progression of a disease or biological condition, to more precisely stratify patients in a clinical trial and/or to optimize a therapeutic approach (G) to treating a condition.
  • Cellular systems biology is defined as the investigation of the integrated and interacting networks of genes, proteins, and metabolic reactions that give rise to function and life. Cells in tissues, as complex systems, exhibit properties that are not anticipated from the analysis of individual components, known as emergent properties that require analysis of many factors to characterize cellular states. Taylor and Giuliano [10] describe the application of in vitro cell systems analysis to drug discovery. In this analysis, correlation between measurements in individual cells was required to identify and interpret cell responses to drug treatment.
  • Cellular systems biology features are defined as a data measurements or a series of measurements of a particular biological function (typically evidenced by the presence, absence and/or level of one or more biomarkers) made in time and/or space within cells and tissues.
  • biological functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non- coding RNAs and proteins.
  • HCS High Content Screening
  • HCS image analysis tools can also be used to extract data from cells in tissues as part of a cellular systems biology profiling approach that would enable the characterization of complex and emergent properties that arise in living cells and tissue.
  • image analysis software packages including those that are supplied with microscope slide scanning systems could be applied to extract cellular features from images of tissues to build a cellular systems biology profile.
  • Cellular systems biology profiles are defined as the interrelationships between combination of at least about five cellular systems biology features collected from cells within one or more tissue sections from the same sample. These interrelationships are calculated either arithmetically ⁇ e.g., ratios, sums, or differences between cellular systems biology feature values) or statistically (e.g., hierarchical clustering methods or principal component analyses of combinations of cellular systems biology feature values). Cellular systems biology profiles can be used to understand the complex response of cells and tissues to disease and various treatments by characterizing the emergent properties of the cellular systems response.
  • Emergence Complexity and Organization 1 : 49-712.
  • the emergent properties of cells and tissues e.g., growth and division, transformation to a tumor phenotype, etc.
  • Emergent properties are not anticipated from the analysis of individual components, but require analysis of many factors to characterize cellular states.
  • tissue sections have value
  • systems approach wherein, as provided herein, multiple features (e.g., at least about four features, at least about five features, at least about six features, at least about 7-12 features, or more), of a tissue are analyzed, enables a more precise determination of the state of the cells, the tissues, and the organism as a whole.
  • this approach facilitates, for example, the automation of tissue analysis, and the production of tissue profiles for more precise tumor staging, personalized treatments, evaluation of treatment efficacy, and early indication of side effects, as well as improved analyses in animal toxicology studies in drug discovery.
  • Tissues are collections of specific cell types forming interacting colonies of cells. Although cells and tissues are less complex than a complete organism, they possess significant functional complexity allowing a detailed understanding of the cellular basis of disease, treatment efficacy and potential toxicity of treatments. Multicolor fluorescence of multiplexed biomarkers coupled with searchable databases provides the basis for systems cell analysis.
  • cellular systems biology also referred to herein as systems cell biology
  • systems cell biology is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions.
  • a cellular systems biology profile is a systemic characterization of cells in the context of a tissue architecture such that the cells have particular characteristics dependent upon the relationships of different cells within a tissue and the biological or medical state of the tissue. It is the interactions, relationships, and state of the constituents of cells within a tissue that gives rise to the cellular systems biology features that are used to construct a profile.
  • a cellular systems biology profile defines the interrelationships between a combination of at least about five cellular systems biology features collected from cells within one or more tissue sections from the same sample.
  • a cellular systems biology profile is the combination of at least about six , seven, eight, nine, ten, eleven, twelve, or more features.
  • the method comprises obtaining at least two sections from one or more tissue samples.
  • tissue sample can be epithelium, muscle, organ tissue, nerve tissue, tumor tissue, and combinations thereof, hi one embodiment, blood is not a tissue sample.
  • Samples of tissue can be obtained by any standard means (e.g., biopsy, core puncture, dissection, and the like, as will be appreciated by a person of skill in the art). At least one section is labeled with a histological stain, to produce a histologically stained section.
  • histological stains can be any standard stain as appreciated in the art, including but not limited to, alcian blue, Fuchsin, haematoxylin and eosin (H&E), Masson trichrome, toluidine blue, Wright's/Giemsa stain, and combinations thereof.
  • traditional histological stains are not fluorescent. At least one other section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section.
  • the panel of fluorescently labeled reagents comprises a number of reagents, such as fluorescently labeled antibodies, fluorescently labeled peptides, fluorescently labeled polypeptides, fluorescently labeled aptamers, fluorescently labeled oligonucleotides (e.g. nucleic acid probes, DNA, RNA, cDNA, PNA, and the like), fluorescently labeled chemicals and fluorescent chemicals (e.g., Hoechst 33342, propidium iodide, Draq- 5, Nile Red, fluorescently labeled phalloidin), and combinations thereof.
  • Each fluorescently labeled reagent is specific for at least one biomarker.
  • a biomarker is a molecule which provides a measure of cellular and/or tissue • function.
  • a biomarker can be the measure of receptor expression levels, (e.g., estrogen receptor expression levels, Her2/neu expression); transcription factor activation; location or amount or activity of a protein, polynucleotide, organelle, and the like; the phosphorylation status of a protein, etc.
  • a biomarker is a nucleic acid (e.g., DNA, RNA, including micro RNAs, snRNAs, mRNA, rRNA, etc.), a receptor, a cell membrane antigen, an intracellular antigen, and extracellular antigen, a signaling molecule, a protein, and the like.
  • the panel of fluorescently labeled reagents detects at least about four different biomarkers.
  • the panel of fluorescently labeled reagents detects at least about four to about six, to about ten, to about twelve different biomarkers or more.
  • the panel of fluorescently labeled reagents detects at least about three different biomarkers.
  • each fluorescently labeled reagent has different fluorescent properties, which are sufficient to distinguish the different fluorescently labeled reagents in the panel.
  • the detection of a biomarker in one or more sections is a read-out of one or more features of a cellular systems biology profile.
  • a “feature” is a characteristic which provides a measurement or series of measurements of a particular biomarker (which can indicate a biological function) made in time and/or space within cells and tissues.
  • Bio functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non- coding RNAs and proteins, morphology, state of differentiation, and the like.
  • a single biomarker can provide a read-out of more than one feature.
  • Hoechst dye detects DNA, which is an example of a biomarker.
  • a number of features can be identified by the Hoechst dye in the tissue sample such as nucleus size, cell cycle stage, number of nuclei, presence of apoptotic nuclei, etc.
  • the method further comprises imaging the histologically stained section using a first optical mode, which produces a first set of data and imaging the fluorescently labeled section using a second optical mode, which produces a second set of data.
  • the optical mode for imaging can be any mode suitable for this use, e.g., transmitted light microscopy, fluorescence light microscopy, wide field microscopy, confocal microscopy, and combinations thereof, as appropriate.
  • the data produced in either or both of the first set of data and second set of data can be digital data.
  • the first set of data and the second set of data are analyzed to identify five or more features, such that at least one feature is identified in the first set of data and at least one feature is identified in the second set of data.
  • the combination of the five or more features generates a cellular systems biology profile of the one or more tissue samples.
  • the imaging procedures are automated. Furthermore, analyzing the data can be performed manually, by automation or a combination thereof. As will be appreciated by a person of skill in the art, imaging a histologically stained section and imaging a fluorescently labeled section can be done sequentially or simultaneously. In addition, histological labeling and fluorescent labeling can be done sequentially or simultaneously.
  • the method is wholly automated.
  • the method further comprises comparing the cellular systems biology profiles of two or more tissue samples in order to identify similarities, differences, or combinations thereof, of the two or more tissue samples.
  • the two or more tissue samples are serial sections from a single tissue specimen. Serial sections of a single tissue sample are tissue sections which were adjacent to each other in the preparation of two or more sections from a tissue sample.
  • the one or more tissue samples are isolated from one or more animals.
  • the one or more animals are one or more humans.
  • one or more tissue samples are isolated from a human patient at one or more time points, such that at least one tissue sample is isolated from each time point from the same patient.
  • the panel of fluorescently labeled reagents indicate the presence, amount, location, activity, distribution, or combination thereof, of the biomarkers in the fluorescently labeled section.
  • the location of a biomarker can be intracellular, extracellular, within specific intracellular locations, at specific extracellular locations, and combinations thereof.
  • Activity of a biomarker can be the activation state of the biomarker (such as indicated, e.g., by its phosphorylation state, conformation state, or intracellular location, and the like).
  • the cellular systems biology profile is stored in a database for reference, thereby providing a reference cellular systems biology profile in a database.
  • the database is a computer.
  • the database is stored on a server.
  • the reference cellular systems biology profile in the database is compared with a cellular systems biology profile of one or more further samples. This permits the identification of similarities, differences, or a combination thereof, of the cellular systems biology profile of the one or more further samples and the reference cellular systems biology profile.
  • Various methods can be used to compare the cellular systems biology profile of the one or more further samples and the cellular systems biology profile in the database, such as by graphical display, cluster analysis, or statistical measure of correlation and combinations thereof.
  • the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one blood sample obtained from the same source as the one or more tissue samples.
  • the blood sample is a peripheral blood sample.
  • Peripheral blood is the cellular components of blood, consisting of red blood cells, white blood cells, and platelets, which are found within the circulating pool of blood and not sequestered within the lymphatic system, spleen, liver, or bone marrow.
  • the method comprises obtaining at least one blood sample smear from at least one peripheral blood sample from the same source as the one or more tissue samples.
  • peripheral blood samples can be obtained by any standard procedure.
  • the at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents detects at least about four different biomarkers.
  • the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method further comprises imaging the fluorescently labeled blood sample smear with at least a third optical mode, such that the imaging produces a third set of data.
  • the third set of data is analyzed to identify at least about five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear.
  • This method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
  • the at least one peripheral blood sample is taken at the same or different time point as the one or more tissue samples are obtained.
  • more than one peripheral blood sample is taken at different time points, and the cellular systems biology profiles of the more than one peripheral blood samples are compared.
  • the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of one or more peripheral blood samples obtained from the same source as the one or more tissue samples.
  • the method comprises obtaining at least two blood sample smears from one or more peripheral blood samples. At least one blood sample smear is labeled with a histological stain to produce a histologically stained blood sample smear. In addition, at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear.
  • Each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least about four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the histologically stained blood sample smear is imaged with at least a third optical mode to produce a third set of data.
  • the fluorescently labeled blood sample smear is imaged with at least a fourth optical mode to produce a fourth set of data.
  • the third set of data and the fourth set of data are analyzed to identify at least about five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, such that the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears.
  • the method produces a cellular systems biology profile of the one or more peripheral blood samples obtained from the same source as the one or more tissue samples.
  • the one or more peripheral blood samples are taken at the same or different time point as the one or more tissue samples are obtained.
  • the cellular systems biology profiles of the one or more peripheral blood samples are compared.
  • a method for producing a cellular systems biology profile of one or more tissue samples comprises obtaining at least one section from one or more tissue samples. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section, such that each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method further comprises imaging the fluorescently labeled section with at least a first optical mode to produce a first set of data which is analyzed to identify at least about five or more features, wherein at least one feature is identified in the first set of data, and wherein the combination of the five or more features is a cellular systems biology profile the one or more tissue samples.
  • the method produces a cellular systems biology profile of the one or more tissue samples.
  • the method further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
  • the method comprises obtaining at least one blood sample smear from at least one peripheral blood sample.
  • the at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, such that each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method further comprises imaging the fluorescently labeled blood sample smear with at least a second optical mode to produce a second set of data.
  • the second set of data is analyzed to identify at least about five or more features, such that the five or more features is a cellular systems biology profile of the at least one blood sample smear.
  • the method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
  • the method further comprises labeling at least one blood sample smear with a histological stain to produce a histologically stained blood sample smear.
  • the histologically stained blood sample smear is imaged to produce an additional set of data which is analyzed to identify at least one feature, wherein the combination of the five or more features identified in the combination of the histologically stained blood sample smear and the fluorescently stained blood sample smear is a cellular systems biology profile of the one or more blood sample smears.
  • a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer.
  • the method described herein permits, for example, the confirmation of the presence or absence of a cancer, the identification of a cancer, the classification of a cancer stage, the prediction and/or determination of the outcome or prognosis of the cancer, and the response of the cancer to any treatments.
  • the method comprises obtaining at least two sections from one or more tissue samples. At least one section is labeled with a histological stain to produce a histologically stained section. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents comprises fluorescently labeled reagents which can be selected from the group consisting of: i) a set of fluorescently labeled reagents specific for at least four cancer cell biomarkers; ii) a set of fluorescently labeled reagents specific for at least four migratory immune cell biomarkers; iii) a combination of A) a set of fluorescently labeled reagents specific for at least three cancer cell biomarkers and B) a set of fluorescently labeled reagents specific for at least three migratory immune cell biomarkers, and iv) combinations of the above, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers.
  • the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method further comprises imaging the histologically stained section with at least a first optical mode to produce a first set of data and imaging the fluorescently labeled section with at least a second optical mode to produce a second set of data.
  • the first set of data and second set of data are analyzed to identify at least about five or more features, such that at least one feature is identified in each of the first set of data and the second set of data.
  • the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples, and thus the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or the absence of a cancer.
  • the cancer is breast cancer.
  • the fluorescently labeled reagents specific for cancer cell biomarkers detect cancer cell markers such as HER2/neu, estrogen receptor (ER), Ki-67, Cox-2, pi 6 and the like, hi another embodiment, the fluorescently labeled reagents specific for migratory immune cell biomarkers detect migratory immune cell biomarkers such as NK cell biomarkers, LAK cell biomarkers, TRAIL, PDl, biomarkers of immune cell apoptosis, and the like.
  • a feature is a ratio of different migratory immune cell subtypes as detected by the migratory immune cell biomarkers, such that the ratio is indicative of the presence of a cancer, the stage of cancer, the diagnosis of a cancer, the prognosis of a cancer, the absence of a cancer and combinations thereof.
  • the one or more tissue samples is selected from the group consisting a suspected or known cancerous tissue, a lymph node, and a combination thereof.
  • Migratory immune cells are typically white blood cells (leukocytes).
  • examples of migratory immune cell biomarkers include, without limitation, the percentage and ratios of specific migratory immune cells in tumors, tumor draining lymph nodes, non-sentinel lymph nodes and peripheral blood.
  • Examples of migratory immune cells in normal blood include: (1) lymphocytes (25% of white blood cells) which includes T-cells (distinct sub-types), B-cells (distinct sub-types), and natural killer (NK) cells; (2) Neutrophils (65% of white blood cells); (3) Eosinophils (4% of white blood cells) and (4) Monocytes (6% of white blood cells), which includes macrophages (distinct sub-types).
  • the percentage ranges of immune cells in tissues for cellular systems biology profiling comprise one or more of the following: lymphocytes from about 1% to about 90% (with distinct sub-types within this percentage, as will be recognized by a person of skill in the art); neutrophils from about 1% to about 90%; eosinophils from about 0.01% to about 50%; monocytes from about 0.01% to about 50% (with distinct sub-types within this percentage, as will be recognized by a person of skill in the art).
  • the ranges of ratios of immune cells in tissues for cellular systems biology profiling comprise one or more of the following: T-cell lymphocytes / B-cell lymphocytes from about 0.1 to about 1000; dendritic cells / lymphocytes from about 0.01 to about 1000; macrophages / lymphocytes from about 0.01 to about 1000; lymphocyte sub-set / lymphocyte sub-set from about 0.01 to about 1000.
  • the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
  • the method comprises obtaining at least one blood sample smear from at least one peripheral blood sample and labeling the at least one blood sample smear with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear.
  • Each fluorescently labeled reagent is specific for a biomarker, and the panel of fluorescently labeled reagents detects at least about four different biomarkers.
  • the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method further comprises imaging the fluorescently labeled blood sample smear with at least a third optical mode to produce a third set of data.
  • the third set of data is analyzed to identify five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear.
  • the method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
  • the at least one peripheral blood sample is taken at the same or different time point as the one or more tissue samples are obtained. In another embodiment, more than one peripheral blood sample is taken at different time points, and the cellular systems biology profiles of the more than one peripheral blood samples are compared.
  • the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
  • the method comprises obtaining at least two blood sample smears from one or more peripheral blood samples and labeling at least one blood sample smear with a histological stain to produce a histologically stained blood sample smear.
  • the method further comprises labeling at least one blood sample smear with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, such that each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
  • the method also comprises imaging the histologically stained blood sample smear with at least a third optical mode to produce a third set of data and imaging the fluorescently labeled blood sample smear with at least a fourth optical mode to produce a fourth set of data.
  • the third set of data and the fourth set of data are analyzed to identify at least about five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, such that the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears.
  • the method produces a cellular systems biology profile of one the or more peripheral blood samples obtained from the same source as the one or more tissue samples, wherein the tissue sample is profiled for the presence or absence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer of the absence of a cancer.
  • the one or more peripheral blood samples are taken at the same or different time points as the one or more tissue samples are obtained.
  • more than one peripheral blood samples are taken at different time points, and the cellular systems biology profile of the more than one peripheral blood samples are compared.
  • a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
  • the method comprises obtaining at least two sections from one or more tissue samples. At least one section labeled with a histological stain to produce a histologically stained section and at least one section is with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
  • the panel of fluorescently labeled reagents comprises a set of fluorescently labeled reagents selected from the group consisting of i) a set of fluorescently labeled reagents specific for cell metabolism biomarkers, ii) a set of fluorescently labeled reagents specific for DNA damage biomarkers, iii) a set of fluorescently labeled reagents specific for cell morphology biomarkers, iv) a set of fluorescently labeled reagents specific for DNA damage biomarkers, v) a set of fluorescently labeled reagents specific for cell differentiation biomarkers, vi) a set of fluorescently labeled reagents specific for stress-induced transcription activation or inhibition biomarkers, vii) a set of fluorescently labeled reagents specific for phosphorylation status of stress kinase biomarkers, viii) a set of fluorescently labeled reagents specific for apoptosis or necrosis biomarkers
  • the histologically stained section is imaged with at least a first optical mode to produce a first set of data.
  • the fluorescently labeled section is imaged with at least a second optical mode to produce a second set of data.
  • the method further comprises analyzing the first set of data and second set of data to identify at least about five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data.
  • the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples.
  • the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
  • the one or more tissue samples is one or more liver tissue samples.
  • Staining and Transmitted Light Imaging in Pathology, Toxicology and Personalized Medicine Standard histological methods for staining and imaging of tissue sections in Pathology, and Toxicology were developed to meet the needs of pathologists and toxicologists to view the sections and make a determination based on experience and knowledge. Stains such as H&E (Hematoxylin and Eosin), congo red, Gram bacterial stain and others provide the means to label various cell types and structures, to facilitate interpretation.
  • H&E Hematoxylin and Eosin
  • Fluorescent labeling technologies especially when coupled with antibodies or other molecularly specific biomarkers or tags such as aptamers, allow for very specific labeling of cellular components, high signal to background, the ability to distinguish multiple labels on a single specimen, and the ability to detect comparatively small numbers of targets in each cell. While these properties make fluorescence nearly ideal for automated imaging, the use of fluorescence in visual interpretation is more limited due to bleaching, limited spectral response of the eye, and the limited dynamic range of the eye. Efforts to automate pathology have principally been guided by the staining and interpretation methods used by the pathologist.
  • Drug Discovery On average, pharmaceutical companies spend more than $1 billion to bring a new drug to market, yet despite this large investment of time and resources, the frequency of drug failure is high. Poor efficacy and drug induced toxicity continue to be major causes of these failures [11, 12]. Furthermore, many candidate drugs fail late, in animal testing or clinical testing, after significant investment in development. Clearly, improved methods of functional assessment are needed in drug discovery, as well as in other fields such as environmental health and industrial safety. Efficacy and toxicity studies are carried out at several points during drug development including cell-based assays, ADME animal studies and clinical trials. Improvements in the reliability of tissue analysis are expected to improve the reliability and safety of drug testing.
  • Genomics and proteomics have laid the groundwork for diagnostic and therapeutic treatments that are customized for each individual patient. This personalized medicine is based on a systems approach to disease which takes into account a profile of the whole patient, to determine the most effective therapy [2].
  • the molecular information derived from genomics and proteomics, and in particular those genes and proteins that have been correlated with particular disease conditions, often referred to as biomarkers, is certainly a valuable source of patient data, but the customization of the treatments will still be limited to well characterized classes of biomarkers, since therapies cannot be tested for every individual genome..
  • Environmental Toxicology The challenge in environmental toxicology is to assess the impact of a growing list of natural and man-made substances on human health. Several factors complicate the problem: increasing large numbers of substances must be tested; the complexities of environmental exposure require testing over a broad range of exposure mechanism, concentration and time; and uncertainties regarding the influence of age and genetic variability on the results. Reliable means to improve the efficiency of testing and evaluation are actively being sought by the National Toxicology Program at the National Institutes of Health.
  • Biomedical research Cell analysis is routinely used in basic biological research as well as in medical research. In both cases the cell analysis is usually focused on a single cellular process, as there are limited tools available for analyzing complex, multi-component system responses. Systems biology is an emerging research field focused on the interactions between system components and pathways.
  • In vivo toxicology measures acute and chronic toxicity in several areas including mutagenicity, organ cytotoxicity, immunotoxicity, neurotoxicity, teratogenicity, and safety pharmacology.
  • In vitro toxicology assays such as CYP450 induction, Ames test, MTT assay and others, are used to measure these functional responses.
  • In vitro toxicology assays are typically cell based assays which use a variety of cell types including hepatocytes, cardiomyocytes, and others.
  • Toxicogenomics uses a combination of traditional genetics and toxicology to identify patterns of gene expression that are associated with toxic effects. Toxicogenomics profiles typically include information such as nucleotide sequences, gene expression levels, protein synthesis, protein function and some phenotypic responses.
  • One goal of toxicogenomics is to identify a sequence of genomic events that lead to a toxic biological response. [13].
  • Cell-Based Assays of Cytotoxicity are designed to detect a specific endpoint in a population of cells. Examples include trypan blue staining, in which cell death is assessed microscopically by measuring the uptake of trypan blue dye that is excluded by live cells. Other vital stains and fluorescent DNA-binding dyes which are also excluded from live cells can also be used. In another assay format, live cells are labeled with a probe which is released upon cell death. Toxicity can also be assessed by measuring specific cellular functions. One of the more common assays is the MTT assay, where cell proliferation is measured by the activity of a mitochondrial enzyme. Other assays measure specific cellular markers.
  • Examples include measurement of the activation of markers associated with the inflammation such as PGE-2, TNF ⁇ , ILIb and other interleukins.
  • Assay formats can be in live cells, fixed cells or cell extracts. Many of the same biomarkers used in these assays will be useful as components of a panel of tissue based cellular biomarkers.
  • Metabolism Drug effect on metabolism is measured by radioactive precursor uptake, thymidine, undine (or uracil for bacteria), and amino acid, into DNA, RNA and proteins. Carbohydrate or lipid synthesis is similarly measured using suitable precursors. Turnover of nucleic acid or protein, or the degradation of specific cell components, is measured by prelabeling (or pulse labeling) followed by a purification step and quantitation of remaining label or sometimes by measurement of chemical amounts of the component. Energy source metabolism is also analyzed for optimal cell growth.
  • Light microscopy shows the general state of cells, and combined with trypan blue exclusion, the percent of viable cells. Small, optically dense cells indicate necrosis, while bloated "blasting" cells with blebs indicate apoptosis. Phase microscopy views cells in indirect light; the reflected light shows more detail, particularly intracellular structures. Fluorescence microscopy detects individual components in cells, after labeling with selective dyes or specific antibodies, and can be used to identify cellular features associated with metabolic states.
  • High Content Screening was developed as a method whereby one or more cellular features are measured and analyzed in arrays of cells to identify a cellular functional response [5, 14, 15].
  • an HCS assay might be used to measure the activation of a particular receptor [16], mitochondrial activity [17], the onset of apoptosis [5, 18], or another cellular function.
  • Each of these cellular features represents a measurement of particular cellular component.
  • a single cellular feature is sufficient to indicate a single cellular function or response.
  • the measurement of several features is required to specifically indicate a cellular response.
  • a commercial apoptosis assay uses four cell features to more specifically indicate apoptosis. These features are interpreted based on the knowledge of the biology of apoptosis.
  • Multiparameter cytotoxicity assays have been developed by nearly all vendors of HCS technologies. These assays are typically two to four parameter assays which measure cellular features related to cell death, either by necrosis or apoptosis. These assays have been applied in drug discovery, and testing for environmental agents of biowarfare [19] on cultured cells and primary cell preparations. Many of the biomarkers used in HCS can also be used in combinations as components of a feature vector of cellular states in tissue sections and other tissue specimens. Reagent Technologies: Multiple reagent technologies are available to assay cellular functions.
  • Fluorescent reagent technologies have matured over the last two decades, with probes available to label subcompartments, localize proteins, label membranes, respond to membrane potentials, sense the local chemical environment, read out molecular mobility, and provide many other measurements [20]. Coupled with antibodies, immunofluorescence labeling provides an easy method for detecting and localizing proteins or protein variants such as phosphorylated proteins. Cells can be engineered to express proteins tagged with any of the color variants of fluorescent proteins [21, 22], and these fluorescent proteins can be further engineered to create biosensors, indicators of specific cellular functions [16, 23-25].
  • a variety of labels can be combined in a single sample preparation to provide for the measurement of many features in each individual cell in a population, as well as in the population as a whole [10, 26].
  • Quantum dots with their single excitation wavelength and narrow emission bands, provide the potential for even higher degrees of multiplexing within an assay [27].
  • the rainbow of fluorescent probes there are a number of bioluminescent and chemiluminescent reagents that can be effectively used in cell based assays [28, 29].
  • Multiparameter High Content Screening Profiles A recent comparison of the performance of a panel of cytotoxicity assays, including DNA synthesis, protein synthesis, glutathione depletion, superoxide induction, Caspase-3 induction, membrane integrity and cell viability found that these assays on average had only half the predictive power of animal studies [H]. In contrast, a relatively simple four parameter high content screening assay using human hepatocytes was found to be more predictive than animal-based toxicity assays (O'Brien, P. J.; Irwin, W.; Diaz, D.; Howard-Cofield, E.; Krejsa, C. M.; Slaughter, M.
  • This classifier allows the use of Boolean operations to combine the outputs from several assay features into a single result [32]. These Boolean operations allow the assay developer to define an output that combines several feature measurements. This is useful in expanding the scope of some HCS assays, but has limited features, and is certainly not designed for, nor would it be easy to use with multidimensional feature sets.
  • the invention described herein is an improved method for characterizing patient tissue specimens based on the integration of specific fluorescence labeling technologies with image acquisition and image analysis to create tissue marker profiles.
  • the invention also discloses the use of the profiles to classify tissue specimens for the purposes of identifying patient medical conditions, such as tumor staging and other disease states, as well as response to treatment.
  • One aspect of this invention is the integration of the use of traditional histological staining and transmitted light-based imaging with panels of molecularly specific, fluorescently labeled biomarkers to correlate morphometric interpretations with biomarker multiplexing in a "cellular systems biology profile.”
  • the outcome is a powerful machine-learning platform where the instrument is fast and the software is simple.
  • FIG. 3 illustrates the relationships between Systems Biology, Cellular systems biology, cellomics, Genomics, Proteomics and Metabolomics.
  • Cellular systems biology is the study of the cell as the basic unit of life: an integrated and interacting network of genes, proteins and biochemical reactions which give rise to functions and life.
  • the cell is the simplest functional biological system, and therefore an ideal system from which to extract knowledge about biological systems.
  • Cellular systems biology involves the application of cellular analysis technologies to the understanding of how the interactions of cellular components gives rise to the complex biochemical and molecular processes that contribute to cell functions. These cell functions include complex behavioral responses of cells to environmental changes as well as experimental treatments. As illustrated in FIG. 3 Cellular systems biology is a component of Systems Biology.
  • the present invention relates to a method for identifying biological conditions in higher level organisms, including humans, from "systems-based" panel or panels of measurements of cellular and/or tissue features in tissue preparations, including blood, including sections, smears and other cellular tissue preparations.
  • the "systems-based" panel of measurements within the same samples dramatically extends the present methodology that focuses on individual or a few parameters to the measurement and subsequent analysis of the systems response profile from the tissue investigated.
  • the methods of this invention also provide a means to quantify the similarity of biological states and predicted modes of action based on the tissue system profiles.
  • There are many applications which will benefit from the use of this invention including animal testing in drug discovery and environmental health, medical diagnostics and human clinical trials. Application of this technology will improve the efficiency and reduce the cost of drug development. The invention will also improve the efficiency of environmental toxicology testing.
  • FIG. 5 illustrates an example of an embodiment of the invention which comprises a panel of assay function classes used to profile toxicity.
  • function classes include Stress Pathways, Organelle Function, Cell Cycle Stage, Morphology Changes, Apoptosis and DNA Damage.
  • Other function classes can be used in toxicity assessment and other functional applications of this method, as will be appreciated by a person of skill in the art.
  • the methods of this invention can be used to validate additional assays and function classes which can be added to a profile to improve the sensitivity, specificity or range of applicability of a specific embodiment of this invention.
  • one or more assays are selected to be used to measure one or more cellular systems biology features of cells within a tissue as an indication of a response in that assay function class.
  • cellular systems biology feature measurements can be made on cells or tissues
  • FIG. 6 a similar high content screening assay with multiple features for cells in arrays is illustrated in FIG. 6.
  • representative images from each channel of a multiplexed high content screen are shown.
  • Algorithms are used to extract information from the images to produce outputs of at least four different cell features including nuclear size and shape, cell cycle distribution, DNA degradation, the state of the microtubule cytoskeleton, the activation state of the tumor suppressor p53, and the phosphorylation state of histone H3, a protein involved in the regulation of the cell cycle.
  • Assays can be combined in two or more assay plates to produce a compound profile with six or more features.
  • Assays such as this which include image analysis algorithms with multiple output features are available from a variety of commercial sources, especially HCS technology vendors such as Cellomics (Pittsburgh, PA), GE Healthcare (Piscataway, NJ), Molecular Devices (Sunnyvale, CA), and others, and can be implemented in any one of the standard image analysis software packages.
  • the output features from the combination of assays, both commercial and custom developed, are combined to form a single response profile.
  • assays are selected from at least about four of the function classes in FIG. 5, to provide a sufficiently broad profile for predicting higher level integrated functions.
  • One embodiment of this invention employs a panel of assays with one from each of these function classes.
  • assays are used first to build a predictive toxicology knowledgebase, and then to generate profiles of test compounds, to compare with the classes in the knowledgebase, and thereby to predict toxic affects of the test substances.
  • Another embodiment of the invention uses all the assays listed in FIG. 5 to produce a more extensive profile, and then uses a statistical method such as principle components analysis to identify the features with the highest predictive power for a selected profile of toxicology parameters.
  • analyses can include combinations of assays where individual tissue cells are measured, along with higher throughput assays where the population of tissue cells or a region of a tissue section is analyzed as a whole for morphometry, texture, intensity, or other features, as will be appreciated by a person of skill in the art.
  • FIGS. 7 and 8 illustrate a flow diagram for two embodiments of the invention.
  • the procedures in FIGS. 7 and 8 illustrate separate procedures.
  • the procedure in FIG. 7 illustrates the procedure used to populate the tissue profile database and create the classes of response profiles linked to the histological determinations.
  • the procedure in FIG. 8 illustrates the process for using the profile database to predict the classify tissue and identify medical states.
  • the procedure in FIG 8 comprises the following steps: 1. Tissue samples are prepared on slides or other carriers. 2. The tissues sections are fixed and stained with labels specific to the biomarker of interest. 3.
  • the slides are read on an imaging system, such as an HCS reader, high throughput slide-scan reader, automated microscope or other detector. 4.
  • Assay algorithms are applied to convert raw image data to assay data points. 5.
  • the assay data points are clustered to produce response classes. 6. Responses classes are used to create a response profile for each of the classes. 7. Response profiles are established for the cells in control tissue specimens in each slide set. 8. Response profiles are clustered to identify unique profiles which can be used to classify and predict functional responses.
  • the procedure illustrated in FIG. 8 is used to evaluate substances for physiological effects. It comprises a sequence of steps: 1. Samples are prepared on slides or other carriers. 2. The cells are fixed and stained with labels specific to the biomarker of interest. 3. The plates are read on an imaging system, such as an HCS reader, high throughput slide-scan reader, automated microscope or other detector. 4. Assay algorithms are applied to convert raw image data to assay data points. 5. The tissue cell features are classified based on the assay data points. 6. The database is searched for physiological response profiles that match the cellular response profiles. 7. Predictions for physiological responses are made based on similarity of response profiles. 8. A report is generated tabulating the probability of each physiological response based on the substance response data.
  • FIG. 7 illustrates the overall sample flow while processing tissue sections to produce cellular systems biology profiles.
  • a slide set comprises two or more tissue sections, each of which is used to collect a cellular systems biology profile.
  • Each tissue section in the set produces an image set of images from one or more fields in each tissue section, at each of the wavelengths to be analyzed.
  • Analysis of the image set produces a set of cellular systems biology features.
  • the cellular systems biology features are processed and clustered to produce a cellular systems biology profiles to go into the data base, or to be used to search the data base to identify probable modes of physiological response or to set priorities for patient stratification.
  • KS values are one means to characterize a population and provide a measurement that can be used to cluster samples from many patients or other tissue sources.
  • cellular systems biology features based on KS values can be clustered by agglomerative clustering or other clustering methods, to build cellular systems biology profiles that identify tissues with similar cellular systems biology profiles.
  • Other methods in addition to KS analysis can be used to process data prior to clustering, and a variety of clustering algorithms can be usefully applied.
  • FIG. 8 illustrates one embodiment of the invention, wherein the data flow is used to generate response profiles for a panel of tissue samples or tissue assays.
  • Tissue samples from sources with known conditions or medical outcomes are processed to produce cellular response profiles, which are merged with other information on physiological conditions.
  • the combined profiles of each tissue are clustered to identify unique profiles that can be used to distinguish classes of response.
  • the response classes are stored in a database for use in classifying test samples.
  • Test tissue samples are processed to produce cellular response profiles that are then matched to those in the database, and based on the similarity of the response to the database profiles, probabilities are calculated for each of the reference response profiles in the database, producing a similarity profile.
  • Algorithms The algorithms, custom designed or encapsulated in the application software provided by HCS vendors, or other imaging software providers, produce multiple numerical feature values (cellular systems biology features) such as subcellular object intensities, shapes, and location for each cell within an optical field.
  • the vHCSTM Discovery Toolbox (Cellomics, Inc), Metamorph (Molecular Devices), software from GE Healthcare and other HCS and image analysis packages can be used to batch analyze images following acquisition. Contingent on the type of tissue sample and its preparation, the total number of cells measured per sample is typically in the range of at least about 100 to at least about 10000, depending on the heterogeneity of the cellular response and the sensitivity of the assay. Examples of assay output parameters illustrate the function of application software.
  • the average nuclear intensity value for each cell can be used.
  • Nuclear condensation produces larger average nuclear intensity values while nuclear enlargement accompanied by DNA degradation produced smaller average nuclear intensity values relative to normal cells.
  • the measurement of histone H3 phosphorylation is obtained using the average nuclear intensity of cells labeled with antibodies specific for phosphohistone H3 as previously reported.
  • KS goodness of fit analysis KS value
  • the testing for significant changes in fluorescence-derived histograms is used to calculate KS values for replicate control samples and use these data to set a threshold (e.g., critical value), above which, a cellular systems biology feature response would be considered significant [36].
  • the one-dimensional KS test can be adapted to two dimensions as described by Peacock [37] and further refined by Fasano and Franceschini [38].
  • the two-dimensional cell population data distributions representing two physiological parameters from a cellular systems biology feature set are compared to the two-dimensional cell population data distributions obtained from multiple specimens.
  • each distribution is divided into quadrants defined by the median x and y axis values calculated from the untreated cell data distributions.
  • the two-dimensional KS value was then found by ranging through all four quadrants to find the maximal difference between the fraction of cells in each treated quadrant and the fraction of cells in each corresponding untreated quadrant.
  • the heterogeneity of cell populations within tissues can also be analyzed with other statistical methods to evaluate cellular systems biology profiles.
  • all the cell feature values from each cell are combined to create a cellular systems biology profile.
  • the cellular systems biology profiles can consist of the actual measured values, and/or the principal components of the measured values, identified by standard methods [39, 40].
  • the cellular systems biology features from each population of tissue cells and from different samples are clustered using standard methods [39, 40], to produce cellular systems biology profiles. These profiles are used to build a classifier. All the cells in a single tissue sample, and therefore characteristic of the same medical condition, are classified into these response classes. The percent occupation of each of these classes then becomes a population response profile for that sample.
  • the cellular systems biology profiles from the samples are linked to the cellular systems biology profiles (e.g., toxicity response profiles) from the reference samples and stored in the database.
  • the cellular systems biology profiles from the test samples are classified using a probabilistic classifier based on the cellular systems biology profiles of the reference samples in the database to predict toxicological responses or to stratify patients.
  • Other embodiments use alternative analysis algorithms or methods to cluster cell response profiles and create a classifier based on the known properties of a training set of tissue sections.
  • the liver a gland comprised of a host of cell types, performs both exocrine and endocrine functions that are regulated by appropriately orchestrated cellular activities. Furthermore, the liver is also responsible for the metabolism of drugs and steroids, many of which target their toxic activities to one or more cell types present in the liver. Other important functions of the liver include deiodination of triiodothyronine and thyroxine, gluconeogenesis and glycogenolysis, maintenance of normal glucose concentration in blood, etherification of free fatty acids into triglycerides, storage of glycogen, fat, and iron, detoxification of poisons and hydrogen peroxide, and hematopoiesis from the second to the eighth month of intrauterine life.
  • liver a cellular systems biology characterization of cells within the intact structure of the liver provides one of the most relevant profiles of normal or diseased tissue, and the effects that chemical compounds have on the liver as a living system.
  • the intact liver like other glands, is comprised of a stroma and a highly vascularized and innervated parenchyma. Tissue sections of liver will therefore be comprised of several cell types including:
  • Nerve fibers cellular processes that accompany blood vessels to innervate the parenchyma
  • Capillary endothelium cells forming the walls of blood vessels 4.
  • Kupfer cells specialized macrophages
  • Fat cells store triglycerides
  • Blood cells cells that include erythrocytes, immune cells, and platelets 7.
  • Hepatocytes the most prevalent cell type in the liver. Hepatocytes perform most of the functions of the liver listed above.
  • biomarkers that can be combined in various combinations to profile the systems response of liver tissue to disease or compound treatment:
  • Metabolism biomarkers
  • Cytochrome P450 isotypes - expression levels and isotype ratios in hepatocytes.
  • P-glycoprotein activity expression level of a membrane-bound protein that pumps multiple compound substrates out of a cell, especially hepatocytes.
  • DNA damage biomarkers • Cell cycle regulation — The distribution of the total DNA content within the nucleus of a cell contained within a tissue slice can be determined using a nuclear label such as Hoechst 33342, Draq-5, or propidium iodide. • Nuclear morphology and chromatin condensation — Nuclear damage can sometimes be correlated with a change in nuclear morphology or the . condensation state of the chromatin. The morphology (e.g., shape and size) or the structure of the chromatin (brightness per unit area) of a nucleus contained within a tissue slice can be determined using a nuclear label such as Hoechst 33342, Draq-5, or propidium iodide.
  • • 8-oxoguanine Oxidative damage to DNA often generates an oxidized analog of guanine. Increased 8-oxoguanine signals that the DNA in a cell has been damaged.
  • • Activation of DNA repair proteins (APE/ref- 1) The DNA in hepatocytes or any other cells present in liver that contain DNA are susceptible to damage due to disease or compound treatment. Changes in the expression level of APE/ref- 1 signals that the DNA damage response mechanism has been activated within a cell.
  • Histone H2A.X phosphorylation The DNA in hepatocytes or any other cells present in liver that contain DNA are susceptible to damage due to disease or compound treatment. Phosphorylation of histone H2A.X signals that the DNA damage response mechanism has been activated within a cell. p53 protein activation.
  • Immune cell presence and activity biomarkers • The percentage and ratios of specific migratory immune cells in hepatocytes, lymph system, and blood supply. • Phenotypes of key immune cell types in liver cancer tissues that reflect either an anti-tumor or tumor-supporting function.
  • NK and LAK cell activity to characterize anti-tumor surveillance
  • tissue preparation In one embodiment, a small animal such as a mouse or a rat is treated with one or more test compounds for various lengths of time (I min to 21 d). In another embodiment, a small animal model of disease including metabolic models such as diabetes, cancer, or other models that either directly or indirectly involve the liver will be used. In yet another embodiment, human liver tissue from diseased or compound treated patients will be used.
  • tissue samples will be prepared. Tissue samples will be processed as either frozen sections or formaldehyde fixed paraffin-embedded sections. In addition, tissue samples will also be obtained for gene expression analysis.
  • the optimal combination (multiplexing) of the liver tissue biomarkers will be the key to creating an optimal cellular systems biology profile of the tissue.
  • the optimal number of number of multiplexed biomarkers will range from about four to about twelve biomarkers.
  • Normal, diseased, and treated tissue samples will be prepared. Tissue samples will be processed as either frozen sections or formaldehyde fixed paraffin-embedded sections. In addition, tissue samples will also be obtained for gene expression analysis.
  • liver tissue analysis a. Gene expression profiling is performed that compares "normal" liver tissue with tissues from diseased or compound treated animals. b. Gene expression informatics - Gene expression profiles analyzed by informatics tools to characterize gene expression as a function of disease or compound treatment to identify gene products. c. Gene products prioritized based on known reference points from normal liver tissue and then antibodies acquired or produced to create test panels. 2. Combinations of histological stains and key biomarkers multiplexed for fluorescence-based immunocytochemistry of the "functional biomarkers": a. Multiple 5 ⁇ m sections prepared from liver tissue. The first section labeled with H&E or other histological stain for traditional pathological analysis.
  • the successive sections processed for multiplexed, fluorescence-based cytometry are processed for multiplexed, fluorescence-based cytometry.
  • some sections will be labeled with multiplexed panels of antibodies to key migratory immune cells; including lymphocytes (e.g. CD3 and CD8).
  • lymphocytes e.g. CD3 and CD8.
  • the level of immune cell activation, concentration and organization will be an important element of the profile.
  • liver tissue slices are labeled for two or more biomarkers to profile differences between non-diseased and diseased or non-treated and treated animals.
  • Biomarkers of a wide range of tissue functions are preferable since they provide breadth to the systems profile of the tissue.
  • the number of biomarkers in one embodiment is about four to about ten biomarkers, and multiple biomarkers can be labeled in the same tissue section. This permits the comparison of some biomarker activities within the same cells.
  • a rat is treated with an apoptosis-inducing compound such as paclitaxel or camptothecin for times ranging from about 30 min to about 21 d using multiple doses in the range from about 1 ⁇ g/kg up to about 100 mg/kg.
  • an apoptosis-inducing compound such as paclitaxel or camptothecin for times ranging from about 30 min to about 21 d using multiple doses in the range from about 1 ⁇ g/kg up to about 100 mg/kg.
  • the animal is sacrificed and the liver tissue either frozen and sectioned or fixed with a chemical such as formaldehyde and then impregnated with paraffin using standard methods before sectioning.
  • a hematoxylin and eosin (H&E) stain can then be performed on one or more sections to provide a sample for traditional, transmitted light-based pathology interpretation.
  • Other sequential sections can be labeled with combinations of fluorescent immunoreagents and physiological indicator dyes for image-based analysis, for
  • Anti-cytochrome c as a biomarker of mitochondrial number, size and shape.
  • Anti-NF-kappa-B as a biomarker of inflammation-related cell signaling.
  • Anti-activated-caspase 3 as a biomarker of apoptosis.
  • Anti-PMP70 as a biomarker of peroxisome size and number.
  • Anti-cytochrome P450 as a biomarker of hepatocyte metabolic activity.
  • Cancer is a systems biology disease that requires a systems biology approach to create better stratification of individual patients for better diagnostics and treatments. Cancer is also an inflammatory process that involves the full range of the immune response. Therefore, tumors contain a combination of cancer cells at different stages of evolution, normal cells and an infiltration of the migratory immune cells such as dendritic cells, macrophages and lymphocytes. Tumor "cellular systems biology" characterization should therefore be a combination of tumor cell biomarkers and immune cell biomarkers. A key to tumor cellular systems biology is the use of a multiplexed panel of tumor biomarkers for cancer cells and immune cells that will better stratify patients.
  • systems profile of the tumor including multiplexed breast cancer biomarkers and migratory immune cell presence and state of activation. 6. Allows implementation of automated imaging quantitation of the system. 7. Allows correlation of the presence and state of activation of the migratory immune cells with the presence and state of activation of the immune cells in the lymph nodes and peripheral blood. 8.
  • Stratification and diagnostic tests can be produced from either/or tissue-based profiles or peripheral blood profiles based on the tissue-based profile data.
  • the multiplexed, fluorescence-based biomarkers can be a combination of specific reagents to detect specific proteins and post-translational modifications of the proteins, specific RNA species, including micro-RNA's either coding or non-coding in cells. Measurement of specific protein expression and state of activation, as well as the presence of specific micro RNA's within cells and tissues are key "functional" read-outs. The expression of a gene is only one element of the systems biology and the present genomic tests are only correlations of gene expression without any functional information.
  • RNA molecules whose expression level, cellular localization and post-translational modification are responsible for carrying out normal and abnormal functions.
  • Specific microRNA's have also been shown to be disease specific and are critical in regulating gene expression, similar to regulatory proteins.
  • tumors are systems in that they are a complex integration of normal cells, a range of genetically evolving cancer cells and migrating immune cells. Therefore, a cellular systems biology profile of multiple protein and/or micro RNA biomarkers is important.
  • the immune system becomes dysfunctional early in the process of cancer occurrence and continues throughout the evolution of the cancer stages leading to metastatic disease.
  • the migratory immune cells are attracted to the growing tumors by proinflammatory cytokines and chemotactic factors.
  • Tumor infiltrating lymphocytes release growth factors and cytokines that actually promote growth of the tumors, while the anti-tumor functions are weak or non-existent.
  • Dendritic cells and tumor- associated macrophages present in the tumor exhibit phenotypes that demonstrate a supporting role for tumor growth.
  • Regulatory T cells accumulate in the tumors, as well as in the tumor-draining lymph nodes and peripheral blood of patients. These latter cells actually protect tumor cells as part of the "recognition of self immune process. Therefore, the immune system is mostly a tumor-promoting system and supports the progression and metastasis in most cancers.
  • Gene expression fingerprints from tumor samples have been used to distinguish subtypes of breast cancers and to assign some prognostic index. These gene expression profiles usually identify genetic profile "signatures" indicative of the infiltration of the migratory immune cells. Unfortunately, in methods such as gene expression profiling, the disaggregated tumor samples the "tumor as a system” is lost since the whole tissue architecture and tumor cell-migratory immune cell structural relationships are lost.
  • Tissue sections including tissue micro-arrays (TMA's) used in patient stratification and diagnostic tests are valuable, since the tumor "system” can be analyzed and quantified through the integrated use of traditional transmitted light stains that are standard in pathology and oncology with multiplexed fluorescence- based biomarkers of more functional parameters of both the migratory immune cells and the cancer cells. Therefore, the traditional information from pathology can be combined with panels of biomarkers using multiplexed fluorescence.
  • TMA's tissue micro-arrays
  • the tumor-draining and non-sentinel lymph nodes are important sites of tumor and immune system interactions that could aid in the "functional cellular systems biology signature".
  • the presence of tumor cells in the tumor-draining lymph nodes affects the types and numbers of immune cells within the nodes.
  • the non-sentinel auxiliary nodes can also be influenced by local tumor growth, since it has been shown that CD4 T cells and dendritic cell counts have been used to predict survival in breast cancer patients.
  • tumor progression also can be observed in the peripheral immune system by analysis of the circulating leukocytes, circulating T cells and other immune cells. Therefore, a correlative analysis of the patient's circulating immune cells in the peripheral blood with the tumor "system", as well as lymph node "system” will create the an excellent opportunity to create powerful tests in tumors, lymph nodes and blood.
  • biomarkers that can be combined in various combinations for optimal staging and diagnostic for breast cancer (in one embodiment, the combination of cancer cell and immune biomarkers may be most suitable):
  • Her2/Neu Protein now used as single biomarker
  • TRAIL death receptor ligands
  • biomarkers associated with immune cell dysfunction such as PDl in Tumor Infiltrating Lymphocytes.
  • NK and LAK cell activity to characterize anti-tumor surveillance
  • the optimal combination (also referred to herein as multiplexing) of the cancer cell and immune biomarkers, especially in the tumors, will be the determinative to creating an optimal cellular systems biology profile of the patient.
  • the optimal number of number of multiplexed biomarkers is in the range from about four to about twelve biomarkers.
  • lymphocytes e.g., CD3 and/or CD8.
  • the level of immune cell activation, concentration and organization will be an important element of the profile.
  • the percentage and ratios of specific migratory immune cells in tumors, tumor draining lymph nodes, non-sentinel lymph nodes and peripheral blood will be calculated and used build cellular systems biology profiles.
  • Example percentage ranges of immune cells in tissues are as follows:
  • Lymphocytes 1% - 90% (distinct sub-types within this percentage)
  • Monocytes 0.01% - 50% (distinct sub-types within this percentage)
  • T-cell lymphocyte subtype I / T-cell lymphocyte subtype II 0.01-1000 T-cell lymphocytes / B-cell lymphocytes: 0.1 - 1000
  • Dendritic cells / lymphocytes 0.01 - 1000
  • Macrophages / lymphocytes 0.01 - 1000
  • Lymphocyte sub-set/lymphocyte sub-set 0.01-1000
  • biomarkers that suitably stratify patient samples from stage I to stage IV will be selected for profiling on new patients. New patients will allow the direct correlation of peripheral immune cells with the tumor tissue and lymph node sections.
  • Example of profiling brain tissue for biomarkers of Alzheimer's disease In this embodiment, human brain tissue is obtained, fixed, and sectioned. A subset of sections are labeled with one or more stains to visualize morphological structures within the tissue associated with the pathology of Alzheimer's disease. In one example, a silver-based stain is used to visualize hallmarks of Alzheimer's disease such as neurite plaques and neurons with neurofibrillary tangles [41]. Analysis of the silver-stained tissue from multiple patients before, during, or after treatments with drugs provides data which are then entered into a profile.
  • biomarkers that can be labeled using immunofluorescence approaches include A ⁇ 42, A ⁇ 40, von Willebrand factor, and the microtubule binding protein tau [42]. Other biomarkers are also possible. These include phosphorylated APP
  • biomarkers of other cellular processes can be included in the profile. Profiles built from multiple biomarker labels measured within tissues from a single patient or profiles built from biomarker labels measured in multiple patient tissue samples are clustered to identify unique profiles that can be used to classify and predict possible patient outcomes, or functional responses to drug treatments, or a combination of both.
  • Hood, L. and R.M. Perlmutter The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol, 2004. 22(10): p. 1215-7. 2. Hood, L., et al., Systems biology and new technologies enable predictive and preventative medicine. Science, 2004. 306(5696): p. 640-3.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Multimedia (AREA)
  • Quality & Reliability (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé amélioré pour identifier et interpréter des échantillons de tissus et/ou des cellules dérivées d'échantillons de tissus. Une batterie de réactifs à base de cellules donne un certain nombre de constatations d'états cellulaires ou de marqueurs biologiques qui définissent ensemble une diversité d'états cellulaires ou de marqueurs biologiques dans un échantillon de tissus représentant la nature des systèmes de la biologie. Pour interpréter le profil cellulaire, on utilise des outils informatiques permettant d'identifier des similitudes entre échantillons, des états médicaux in vivo, et de suggérer des options permettant un traitement des états médicaux.
EP07777137A 2006-05-17 2007-05-17 Procédé d'analyse automatique des tissus Ceased EP2027465A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80103506P 2006-05-17 2006-05-17
PCT/US2007/011865 WO2007136724A2 (fr) 2006-05-17 2007-05-17 Procédé d'analyse automatique des tissus

Publications (1)

Publication Number Publication Date
EP2027465A2 true EP2027465A2 (fr) 2009-02-25

Family

ID=38723843

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07777137A Ceased EP2027465A2 (fr) 2006-05-17 2007-05-17 Procédé d'analyse automatique des tissus

Country Status (6)

Country Link
US (3) US8114615B2 (fr)
EP (1) EP2027465A2 (fr)
JP (2) JP5406019B2 (fr)
CN (1) CN101484806A (fr)
CA (1) CA2652562C (fr)
WO (1) WO2007136724A2 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017751A2 (fr) * 2004-08-02 2006-02-16 Cellumen, Inc. Procedes pour la detection d'interactions moleculaires dans des cellules
US20090170091A1 (en) * 2006-01-17 2009-07-02 Kenneth Giuliano Method For Predicting Biological Systems Responses
EP2027465A2 (fr) * 2006-05-17 2009-02-25 Cellumen, Inc. Procédé d'analyse automatique des tissus
WO2007139895A2 (fr) * 2006-05-24 2007-12-06 Cellumen, Inc. Procédé de modélisation d'une maladie
US8060348B2 (en) * 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
US8131476B2 (en) 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
EP2199956A1 (fr) * 2008-12-18 2010-06-23 Siemens Aktiengesellschaft Procédé et système pour la gestion de résultats d'un procédé d'analyse sur des objets manipulés tout au long d'une chaîne de procédé technique
US20110231103A1 (en) * 2010-03-19 2011-09-22 Ye Fang Methods for determining molecular pharmacology using label-free integrative pharmacology
US10018631B2 (en) 2011-03-17 2018-07-10 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
EP2697398A2 (fr) * 2011-04-12 2014-02-19 Gooch & Housego PLC Criblage pap automatisé à l'aide d'une pluralité de biomarqueurs et d'imagerie multi-spectrale
US20120269418A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
US8831327B2 (en) * 2011-08-30 2014-09-09 General Electric Company Systems and methods for tissue classification using attributes of a biomarker enhanced tissue network (BETN)
US20130089248A1 (en) * 2011-10-05 2013-04-11 Cireca Theranostics, Llc Method and system for analyzing biological specimens by spectral imaging
US20140297199A1 (en) * 2011-11-11 2014-10-02 Cold Spring Harbor Laboratory Drug screening method and uses thereof
US8568991B2 (en) 2011-12-23 2013-10-29 General Electric Company Photoactivated chemical bleaching of dyes
US9176032B2 (en) 2011-12-23 2015-11-03 General Electric Company Methods of analyzing an H and E stained biological sample
US8416240B1 (en) * 2012-04-02 2013-04-09 Google Inc. Determining 3D model information from stored images
US9036888B2 (en) 2012-04-30 2015-05-19 General Electric Company Systems and methods for performing quality review scoring of biomarkers and image analysis methods for biological tissue
US8737709B2 (en) 2012-04-30 2014-05-27 General Electric Company Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue
US9798918B2 (en) * 2012-10-05 2017-10-24 Cireca Theranostics, Llc Method and system for analyzing biological specimens by spectral imaging
CN103105324B (zh) * 2013-01-29 2015-08-26 福州迈新生物技术开发有限公司 一种同一切面多靶点蛋白免疫组化或免疫荧光标记的方法
US9488639B2 (en) * 2013-02-25 2016-11-08 Flagship Biosciences, Inc. Cell-based tissue analysis
JP2016513794A (ja) 2013-03-06 2016-05-16 ゼネラル・エレクトリック・カンパニイ Ｈ＆ｅ染色された生体試料を分析する方法
US9372143B2 (en) * 2013-05-15 2016-06-21 Captl Llc Scanning image flow cytometer
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
DK3063291T3 (da) * 2013-10-11 2019-05-06 Ventana Med Syst Inc Multiplex her2 og østrogenreceptor co-farvnings-assays til påvisning af tumorheterogenitet
US9308296B2 (en) 2014-05-05 2016-04-12 Warsaw Orthopedic, Inc. Tissue processing apparatus and method
US10584366B2 (en) * 2014-12-03 2020-03-10 IsoPlexis Corporation Analysis and screening of cell secretion profiles
US10900885B2 (en) 2014-12-19 2021-01-26 Captl Llc Flow cytometry using hydrodynamically planar flow
WO2016103501A1 (fr) * 2014-12-26 2016-06-30 国立大学法人東京大学 Dispositif d'analyse, procédé et programme d'analyse, procédé de production de cellules et cellules
US9784665B1 (en) * 2014-12-29 2017-10-10 Flagship Biosciences, Inc. Methods for quantitative assessment of muscle fibers in muscular dystrophy
US20180040120A1 (en) * 2014-12-29 2018-02-08 Flagship Biosciences, Inc. Methods for quantitative assessment of mononuclear cells in muscle tissue sections
US10036698B2 (en) 2015-06-19 2018-07-31 Captl Llc Time-sequential cytometry
CN104990781B (zh) * 2015-06-29 2018-02-16 中国医学科学院皮肤病研究所 黑素细胞免疫组化苏木素—甲苯胺蓝双重复染法
WO2017091658A1 (fr) 2015-11-25 2017-06-01 Cernostics, Inc. Procédés de prédiction de la progression de l'endobrachyoesophage
US10786298B2 (en) 2016-03-01 2020-09-29 Covidien Lp Surgical instruments and systems incorporating machine learning based tissue identification and methods thereof
US10768114B2 (en) * 2016-04-29 2020-09-08 Synaptive Medical (Barbados) Inc. Multi-modal optical imaging system for tissue analysis
US10568567B1 (en) * 2016-05-31 2020-02-25 Vium, Inc Method of drug approval using motion vector analysis
US10913930B2 (en) 2016-08-09 2021-02-09 Warsaw Orthopedic, Inc. Tissue processing apparatus and method for infusing bioactive agents into tissue
WO2018049418A1 (fr) 2016-09-12 2018-03-15 IsoPlexis Corporation Système et procédés d'analyse multiplexée d'agents immunothérapeutiques cellulaires et autres
WO2018063914A1 (fr) 2016-09-29 2018-04-05 Animantis, Llc Procédés et appareil d'évaluation de l'activité du système immunitaire et de l'efficacité thérapeutique
CA2954115C (fr) * 2016-10-16 2022-04-12 Neil Gordon Quantification de bioanalyte ultra-sensible a partir d'etiquettes quadruplexes auto-assemblees
EP3532984B1 (fr) * 2016-10-27 2024-05-08 Koninklijke Philips N.V. Appareil permettant de déterminer des informations de composition cellulaire dans un ou plusieurs échantillons de tissu
EP3538891B1 (fr) 2016-11-11 2022-01-05 Isoplexis Corporation Compositions et procédés pour l'analyse génomique, intradermique et protéomique simultanée de cellules uniques
CN110431637A (zh) * 2017-02-09 2019-11-08 莱维特医疗公司 用于组织样本处理的系统和方法
CA3068084C (fr) * 2017-09-09 2023-11-28 Neil Gordon Amplification et detection de signal de bioanalyte au moyen d'un diagnostic d'intelligence artificielle
WO2019147908A1 (fr) * 2018-01-26 2019-08-01 Diagnostic Photonics, Inc. Procédé et appareil de classification d'échantillons de base de biopsie avec tomographie par cohérence optique
CN111819443A (zh) 2018-02-28 2020-10-23 日东纺绩株式会社 从固定化细胞或ffpe组织切片脱离增强抗原性的细胞核的方法以及用于该方法的抗原活化剂及试剂盒
US11551043B2 (en) * 2018-02-28 2023-01-10 Visiongate, Inc. Morphometric detection of malignancy associated change
FR3079617B1 (fr) * 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique
HK1257467A2 (zh) * 2018-06-22 2019-10-18 Master Dynamic Limited 癌症细胞检测和成像系统，过程和制品
DE102018005064A1 (de) * 2018-06-26 2020-01-02 Hans-Ulrich Dodt Verfahren für die 3D Pathologie
US12288323B2 (en) 2018-10-17 2025-04-29 Koninklijke Philips N.V. Mapping image signatures of cancer cells to genetic signatures
US12333423B2 (en) 2019-02-14 2025-06-17 Covidien Lp Systems and methods for estimating tissue parameters using surgical devices
US12053231B2 (en) 2019-10-02 2024-08-06 Covidien Lp Systems and methods for controlling delivery of electrosurgical energy
US20230081232A1 (en) * 2020-02-17 2023-03-16 10X Genomics, Inc. Systems and methods for machine learning features in biological samples
CN113376386B (zh) * 2020-03-09 2025-09-02 中国科学院广州生物医药与健康研究院 一种病毒性肺炎的标志物及其应用
CN111539354B (zh) * 2020-04-27 2020-12-15 易普森智慧健康科技（深圳）有限公司 一种液基细胞玻片扫描区域识别方法
EP4158637A1 (fr) * 2020-05-29 2023-04-05 10X Genomics, Inc. Systèmes et procédés d'apprentissage machine d'échantillons biologiques pour optimiser la perméabilisation
CN112051250B (zh) * 2020-09-09 2021-11-23 南京诺源医疗器械有限公司 一种医学荧光成像影像补光调节系统及调节方法
CN113390666B (zh) * 2021-06-17 2023-01-24 安徽科丞智能健康科技有限责任公司 一种检测细胞内化学物质的性能指标方法
JP7283642B1 (ja) 2021-09-29 2023-05-30 日東紡績株式会社 細胞または細胞核の豊富化方法
CN113935983B (zh) * 2021-10-28 2024-08-02 北京中科与点科技中心(有限合伙) 一种核周溶酶体分布全自动定量分析方法
WO2023091967A1 (fr) * 2021-11-16 2023-05-25 The Board Of Trustees Of The Leland Stanford Junior University Systèmes et procédés de traitement personnalisé de tumeurs
US20240125771A1 (en) * 2022-07-27 2024-04-18 National Taiwan University Reaction platform for accelerated biochemical reaction
WO2025171362A1 (fr) * 2024-02-07 2025-08-14 The Board Of Trustees Of The Leland Stanford Junior University Systèmes et procédés d'évaluation de micro-environnements tissulaires et leurs applications

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047321A (en) 1988-06-15 1991-09-10 Becton Dickinson & Co. Method for analysis of cellular components of a fluid
US5733721A (en) 1992-11-20 1998-03-31 The Board Of Regents Of The University Of Oklahoma Cell analysis method using quantitative fluorescence image analysis
US5995645A (en) 1993-08-18 1999-11-30 Applied Spectral Imaging Ltd. Method of cancer cell detection
FI101829B1 (fi) 1995-03-07 1998-08-31 Erkki Juhani Soini Biospesifinen määritysmenetelmä
ATE184613T1 (de) 1995-09-22 1999-10-15 Novo Nordisk As Varianten des grünen fluoreszenzproteins, gfp
WO1997014028A2 (fr) 1995-10-11 1997-04-17 Luminex Corporation Procedes et appareil d'analyse multiplexee de specimens cliniques
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US20060141539A1 (en) 1996-05-30 2006-06-29 Taylor D L Miniaturized cell array methods and apparatus for cell-based screening
AU734704B2 (en) 1996-05-30 2001-06-21 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US6103479A (en) 1996-05-30 2000-08-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US5989835A (en) 1997-02-27 1999-11-23 Cellomics, Inc. System for cell-based screening
DE19634873A1 (de) 1996-08-29 1998-03-12 Boehringer Mannheim Gmbh System zur Unterscheidung fluoreszierender Molekülgruppen durch zeitaufgelöste Fluoreszenzmessung
US7062219B2 (en) 1997-01-31 2006-06-13 Odyssey Thera Inc. Protein fragment complementation assays for high-throughput and high-content screening
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6897017B1 (en) 1997-01-31 2005-05-24 Odyssey Thera Inc. Vivo library-versus-library selection of optimized protein-protein interactions
US7306914B2 (en) 1997-01-31 2007-12-11 Odyssey Thera Inc. Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US5885840A (en) 1997-02-10 1999-03-23 Compucyte Corp. Multiple assays of cell specimens
US6727071B1 (en) 1997-02-27 2004-04-27 Cellomics, Inc. System for cell-based screening
US7853411B2 (en) 1997-02-27 2010-12-14 Cellomics, Inc. System for cell-based screening
US6759206B1 (en) 1997-02-27 2004-07-06 Cellomics, Inc. System for cell-based screening
CA2282658C (fr) 1997-02-27 2003-02-25 Cellomics, Inc. Systeme de criblage de cellules
US6416959B1 (en) 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US7117098B1 (en) 1997-02-27 2006-10-03 Cellomics, Inc. Machine-readable storage medium for analyzing distribution of macromolecules between the cell membrane and the cell cytoplasm
US6756207B1 (en) 1997-02-27 2004-06-29 Cellomics, Inc. System for cell-based screening
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
DE69804446T3 (de) 1997-04-07 2006-08-24 Bioimage A/S Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen
US6259807B1 (en) 1997-05-14 2001-07-10 Applied Imaging Corp. Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images
US6548263B1 (en) 1997-05-29 2003-04-15 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US7160687B1 (en) 1997-05-29 2007-01-09 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
WO1999024563A1 (fr) 1997-11-07 1999-05-20 Iconix Pharmaceuticals, Inc. Procede de caracterisation de cibles genetiques de remplacement
WO1999036564A1 (fr) 1998-01-16 1999-07-22 Luminex Corporation Appareil et procedes d'analyse multiplexee de specimens cliniques
US7166424B2 (en) 1998-02-02 2007-01-23 Odyssey Thera Inc. Fragments of fluorescent proteins for protein fragment complementation assays
US20050221280A1 (en) 1998-02-02 2005-10-06 Odyssey Thera, Inc. Protein-protein interactions for pharmacological profiling
US7282350B2 (en) 1998-02-12 2007-10-16 Immunivest Corporation Labeled cell sets for use as functional controls in rare cell detection assays
JP4374139B2 (ja) * 1998-02-25 2009-12-02 ザ ユナイテッド ステイツ オブ アメリカ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 迅速な分子プロファイリングのための腫瘍組織マイクロアレイ
US6242205B1 (en) 1998-04-24 2001-06-05 Yale University Method of detecting drug-receptor and protein-protein interactions
US6324479B1 (en) 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US5965352A (en) 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
WO2000003246A2 (fr) 1998-07-13 2000-01-20 Cellomics, Inc. Systeme destine a un criblage a base de cellules
EP1114320A2 (fr) 1998-09-18 2001-07-11 Cellomics, Inc. Systeme de criblage cellulaire
CA2345151A1 (fr) 1998-09-22 2000-03-30 Cellomics, Inc. Methodes et appareil de criblage sur la base de cellules avec un reseau miniaturise de cellules
US6146830A (en) 1998-09-23 2000-11-14 Rosetta Inpharmatics, Inc. Method for determining the presence of a number of primary targets of a drug
AU5790199A (en) 1998-10-05 2000-04-26 Duke University Method and apparatus for detecting binding interactions (in vivo)
US6950752B1 (en) 1998-10-27 2005-09-27 Rosetta Inpharmatics Llc Methods for removing artifact from biological profiles
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
DE69903337T2 (de) 1998-10-30 2003-08-21 Cellomics, Inc. Ein screeningsystem auf zellbasis
US6453241B1 (en) 1998-12-23 2002-09-17 Rosetta Inpharmatics, Inc. Method and system for analyzing biological response signal data
EP1141415A1 (fr) 1998-12-23 2001-10-10 Rosetta Inpharmatics Inc. Procedes de discrimination robuste de profils
US6801859B1 (en) 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
US6370478B1 (en) 1998-12-28 2002-04-09 Rosetta Inpharmatics, Inc. Methods for drug interaction prediction using biological response profiles
US6222093B1 (en) 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
ATE239907T1 (de) 1999-02-26 2003-05-15 Cellomics Inc Ein system für zellbasierte reihenuntersuchungen
DE60003171T2 (de) 1999-04-01 2004-04-08 Cellomics, Inc. Methoden zur miniaturisierten zellenanordnung und auf zellen basierendes screening gerät
WO2000070528A2 (fr) 1999-05-14 2000-11-23 Cytokinetics, Inc. Procede et appareil de bioinformatique cellulaire previsionnelle
AU5269900A (en) 1999-05-14 2000-12-05 Cellomics, Inc. A system for cell-based screening
US20030228565A1 (en) 2000-04-26 2003-12-11 Cytokinetics, Inc. Method and apparatus for predictive cellular bioinformatics
AU7131900A (en) 1999-06-21 2001-01-09 Cellomics, Inc. A system for cell-based screening
WO2001007891A2 (fr) 1999-07-27 2001-02-01 Cellomics, Inc. Procedes et appareil de jeu ordonne miniaturise de cellules destines au criblage cellulaire
AU6366200A (en) 1999-07-27 2001-02-13 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
WO2001011341A2 (fr) 1999-08-05 2001-02-15 Cellomics, Inc. Systeme criblage de cellules
US6986993B1 (en) 1999-08-05 2006-01-17 Cellomics, Inc. System for cell-based screening
JP2003506711A (ja) 1999-08-05 2003-02-18 セロミックス インコーポレイテッド 光学システムによる細胞の解析
EP1204869B1 (fr) 1999-08-17 2008-10-22 Luminex Corporation Procede pour detertminer un seul analyte dans un nombre d'echantillons d'origines differentes
US6753413B1 (en) 1999-08-30 2004-06-22 The Hong Kong University Of Science & Technology P35NCK5A binding proteins
AU7579900A (en) 1999-09-15 2001-04-17 Luminex Corporation Creation of a database of biochemical data and methods of use
US6312956B1 (en) 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
EP1283904A2 (fr) 1999-11-03 2003-02-19 Oncotech, Inc. Methodes de prognostic et de diagnostic du cancer
AU1656401A (en) 1999-11-09 2001-06-06 Cellomics, Inc. A system for cell-based screening
WO2001042786A2 (fr) 1999-12-09 2001-06-14 Cellomics, Inc. Systeme de criblage a base de cellules
US7266458B2 (en) 2000-03-06 2007-09-04 Bioseek, Inc. BioMAP analysis
US6763307B2 (en) 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
ATE516497T1 (de) 2000-03-06 2011-07-15 Asterand Acquisition Llc Screening für funktionshomologien
JP2001327296A (ja) 2000-03-15 2001-11-27 Japan Science & Technology Corp 蛋白質−蛋白質相互作用検出方法
WO2001087919A2 (fr) 2000-05-12 2001-11-22 Yale University Methodes permettant de detecter des interactions entre des proteines, des peptides ou leurs bibliotheques au moyen de proteines de fusion
CA2414626A1 (fr) 2000-07-04 2002-01-10 Bioimage A/S Technique permettant d'extraire des informations quantitatives relatives aux interactions entre des composants cellulaires
WO2002018537A2 (fr) 2000-08-29 2002-03-07 Yeda Research And Development Co. Ltd. Methodes d'isolation de genes codant des proteines a fonction specifique et de criblage d'agents actifs d'un point de vue pharmaceutique
US20030096243A1 (en) 2000-09-28 2003-05-22 Busa William Brian Methods and reagents for live-cell gene expression quantification
EP1328880A4 (fr) 2000-10-12 2004-12-15 Iconix Pharm Inc Correlation interactive de donnees de compose et de donnees genomiques
WO2002057297A1 (fr) 2000-11-17 2002-07-25 University Of Massachusetts Utilisation de la proteine zpr1 en guise de sonde moleculaire destinee a la maladie de d'aran-duchenne
US6599694B2 (en) 2000-12-18 2003-07-29 Cytokinetics, Inc. Method of characterizing potential therapeutics by determining cell-cell interactions
WO2002052272A2 (fr) 2000-12-23 2002-07-04 Evotec Oai Ag Methode et procede de depistage permettant de detecter des interactions reversibles proteine-proteine
US6956961B2 (en) 2001-02-20 2005-10-18 Cytokinetics, Inc. Extracting shape information contained in cell images
US7016787B2 (en) 2001-02-20 2006-03-21 Cytokinetics, Inc. Characterizing biological stimuli by response curves
EP1368653B1 (fr) 2001-03-12 2013-01-23 Cellomics, Inc. Methodes pouvant augmenter la capacite d'essais de criblage cellulaire a grande densite
WO2002077903A2 (fr) 2001-03-26 2002-10-03 Cellomics, Inc. Procedes relatifs a la determination de l'organisation d'un constituant cellulaire specifique
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
AU2002256347A1 (en) 2001-04-20 2002-11-05 President And Fellows Of Harvard College Compositions and methods for the identification of protein interactions in vertebrate cells
WO2002093129A2 (fr) 2001-05-15 2002-11-21 University Of Medicine & Dentistry Of New Jersey Methodes d'analyse des interactions entre proteines dans des cellules vivantes et entieres
US8000949B2 (en) 2001-06-18 2011-08-16 Genego, Inc. Methods for identification of novel protein drug targets and biomarkers utilizing functional networks
EP1499885B1 (fr) 2001-08-01 2009-10-21 Cellomics, Inc. Nouvelles proteines de fusion et analyses de detection de liaisons moleculaires
CA2495021A1 (fr) 2001-08-06 2003-07-03 Vanderbilt University Systeme et procedes de mesure d'au moins un taux metabolique de plusieurs cellules
DE10143757A1 (de) 2001-09-06 2003-03-27 Werner M Methode zur Darstellung von Merkmalen in Geweben
US20030096016A1 (en) * 2001-09-07 2003-05-22 Yeda Research And Development Co. Ltd. Methods of kidney transplantation utilizing developing nephric tissue
US20040043436A1 (en) 2001-09-21 2004-03-04 Antonia Vlahou Biomarkers of transitional cell carcinoma of the bladder
GB0123352D0 (en) 2001-09-28 2001-11-21 Koninkl Philips Electronics Nv Image display
WO2003029827A2 (fr) 2001-10-01 2003-04-10 Bioimage A/S Methode amelioree permettant de detecter des interactions entre des constituants cellulaires presents dans des cellules vivantes intactes et d'extraire des informations quantitatives se rapportant auxdites interactions par nouvelle repartition de fluorescence
DE10211653A1 (de) 2002-03-15 2003-10-02 Klaus Pfizenmaier Filament-Rekrutierung fluoreszierender Proteine zur Analyse und Identifikation von Protein-Protein-Interaktionen: FIT (Filament-based Interaction Trap) analysis
US7274809B2 (en) 2002-08-29 2007-09-25 Perceptronix Medical, Inc. And British Columbia Cancer Agency Computerized methods and systems related to the detection of malignancy-associated changes (MAC) to detect cancer
US7865534B2 (en) 2002-09-30 2011-01-04 Genstruct, Inc. System, method and apparatus for assembling and mining life science data
US20050059153A1 (en) 2003-01-22 2005-03-17 George Frank R. Electromagnetic activation of gene expression and cell growth
US7691580B2 (en) 2003-01-29 2010-04-06 Corning Incorporated Reverse protein delivery into cells on coded microparticles
CA2516795C (fr) 2003-02-27 2013-01-15 Immunivest Corporation Cellules tumorales circulantes (ctc) : evaluation precoce du delai avant progression, de la survie et de la reponse au traitement chez les patientes atteintes d'un cancer metastatique
WO2004094992A2 (fr) 2003-04-23 2004-11-04 Bioseek, Inc. Procedes servant a l'analyse de profils d'ensembles de donnees biologiques
EP1620722A4 (fr) 2003-04-23 2008-01-30 Bioseek Inc Procedes de caracterisation de voies de signalisation et composes interagissant avec ceux-ci
US20050014217A1 (en) 2003-07-18 2005-01-20 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
US7235353B2 (en) 2003-07-18 2007-06-26 Cytokinetics, Inc. Predicting hepatotoxicity using cell based assays
US7505948B2 (en) 2003-11-18 2009-03-17 Aureon Laboratories, Inc. Support vector regression for censored data
US7483554B2 (en) 2003-11-17 2009-01-27 Aureon Laboratories, Inc. Pathological tissue mapping
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
CA2576406A1 (fr) 2003-09-03 2005-03-17 Bioseek, Inc. Essais cellulaires permettant de determiner l'effet d'un medicament
US7269517B2 (en) 2003-09-05 2007-09-11 Rosetta Inpharmatics Llc Computer systems and methods for analyzing experiment design
US20050136549A1 (en) 2003-10-30 2005-06-23 Bioimagene, Inc. Method and system for automatically determining diagnostic saliency of digital images
US7760927B2 (en) 2003-09-10 2010-07-20 Bioimagene, Inc. Method and system for digital image based tissue independent simultaneous nucleus cytoplasm and membrane quantitation
WO2005027015A2 (fr) 2003-09-10 2005-03-24 Bioimagene, Inc. Procede et systeme d'analyse quantitative d'echantillons biologiques
US20070083333A1 (en) 2003-11-17 2007-04-12 Vitiello Maria A Modeling of systemic inflammatory response to infection
WO2005055113A2 (fr) 2003-11-26 2005-06-16 Genstruct, Inc. Systeme, procede et appareil d'analyse d'implications causales dans des reseaux biologiques
US20050154535A1 (en) 2004-01-09 2005-07-14 Genstruct, Inc. Method, system and apparatus for assembling and using biological knowledge
WO2005075669A1 (fr) 2004-02-09 2005-08-18 Universität Bonn Procede fonde sur la transcription inverse permettant de detecter l'expression genique dans une cellule
JP4912894B2 (ja) 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
WO2005093561A1 (fr) 2004-02-27 2005-10-06 Bioseek, Inc. Etablissement de profils d'ensembles de donnees biologiques relatifs a l'asthme et a l'atopie
WO2005091203A2 (fr) 2004-03-12 2005-09-29 Aureon Laboratories, Inc. Systemes et procedes pour le traitement, le diagnostic et la prediction de la survenance d'une condition medicale
ES2381644T3 (es) 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
WO2005111243A2 (fr) 2004-05-07 2005-11-24 Cepheid Detection multiplexee d'agents biologiques
JP2005323573A (ja) * 2004-05-17 2005-11-24 Sumitomo Pharmaceut Co Ltd 遺伝子発現データ解析方法および、疾患マーカー遺伝子の選抜法とその利用
KR20070049637A (ko) 2004-07-09 2007-05-11 트리패스 이미징, 인코포레이티드 난소 질환 검출 방법 및 조성물
WO2006017751A2 (fr) 2004-08-02 2006-02-16 Cellumen, Inc. Procedes pour la detection d'interactions moleculaires dans des cellules
CA2575859A1 (fr) 2004-08-11 2006-02-23 Aureon Laboratories, Inc. Systemes et procedes de diagnostic et d'evaluation automatises d'images de tissus
US20060040338A1 (en) 2004-08-18 2006-02-23 Odyssey Thera, Inc. Pharmacological profiling of drugs with cell-based assays
CA2580795A1 (fr) 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methodes et compositions permettant d'evaluer un pronostic de cancer du sein
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
US20060160109A1 (en) 2004-11-22 2006-07-20 Odyssey Thera, Inc. Harnessing network biology to improve drug discovery
US20060159325A1 (en) 2005-01-18 2006-07-20 Trestle Corporation System and method for review in studies including toxicity and risk assessment studies
EP1848825A2 (fr) 2005-02-04 2007-10-31 Rosetta Inpharmatics LLC. Procedes de prevision de la reactivite a la chimiotherapie chez des patientes souffrant du cancer du sein
US9734282B2 (en) 2005-03-28 2017-08-15 Discoverx Corporation Biological dataset profiling of cardiovascular disease and cardiovascular inflammation
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
US20070019854A1 (en) 2005-05-10 2007-01-25 Bioimagene, Inc. Method and system for automated digital image analysis of prostrate neoplasms using morphologic patterns
US7410763B2 (en) 2005-09-01 2008-08-12 Intel Corporation Multiplex data collection and analysis in bioanalyte detection
CA2624086A1 (fr) 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Traitements anticancereux individualises
US7599893B2 (en) 2005-10-13 2009-10-06 Aureon Laboratories, Inc. Methods and systems for feature selection in machine learning based on feature contribution and model fitness
EP1934607B1 (fr) 2005-10-13 2013-08-28 Fundação D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud Analyse immunohistochimique multiplexee in situ
GB2433986A (en) 2006-01-09 2007-07-11 Cytokinetics Inc Granularity analysis in cellular phenotypes
US9133506B2 (en) 2006-01-10 2015-09-15 Applied Spectral Imaging Ltd. Methods and systems for analyzing biological samples
GB2434225A (en) 2006-01-13 2007-07-18 Cytokinetics Inc Random forest modelling of cellular phenotypes
US20090170091A1 (en) 2006-01-17 2009-07-02 Kenneth Giuliano Method For Predicting Biological Systems Responses
MX2008009592A (es) 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
US7790463B2 (en) 2006-02-02 2010-09-07 Yale University Methods of determining whether a pregnant woman is at risk of developing preeclampsia
EP2287327B1 (fr) 2006-03-06 2013-06-05 Ceetox Inc. Procédés in vitro de dépistage de la toxicité de médicament antitumoral
WO2007103492A2 (fr) 2006-03-09 2007-09-13 Cytokinetics, Inc. Modèles de prédiction cellulaire permettant de détecter des toxicités
WO2007103531A2 (fr) 2006-03-09 2007-09-13 Cytokinetics, Inc. Modèles de prédiction cellulaire permettant de détecter des toxicités
GB2435923A (en) 2006-03-09 2007-09-12 Cytokinetics Inc Cellular predictive models for toxicities
GB2435925A (en) 2006-03-09 2007-09-12 Cytokinetics Inc Cellular predictive models for toxicities
WO2007103535A2 (fr) 2006-03-09 2007-09-13 Cytokinetics, Inc. Modèles de prédiction cellulaire permettant de détecter des toxicités
US20070225956A1 (en) 2006-03-27 2007-09-27 Dexter Roydon Pratt Causal analysis in complex biological systems
US8367351B2 (en) 2006-05-05 2013-02-05 Historx, Inc. Methods for determining signal transduction activity in tumors
EP2027465A2 (fr) * 2006-05-17 2009-02-25 Cellumen, Inc. Procédé d'analyse automatique des tissus
WO2007139895A2 (fr) 2006-05-24 2007-12-06 Cellumen, Inc. Procédé de modélisation d'une maladie
US7706591B2 (en) 2006-07-13 2010-04-27 Cellomics, Inc. Neuronal profiling
JP2009544007A (ja) 2006-07-13 2009-12-10 イェール・ユニバーシティー バイオマーカーの細胞内局在性に基づいて癌予後を行う方法
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
WO2008060483A2 (fr) 2006-11-10 2008-05-22 Cellumen, Inc. Biocapteurs d'interaction protéine-protéine et leurs procédés d'utilisation
WO2008115420A2 (fr) 2007-03-15 2008-09-25 Cellumen, Inc. Procédés pour la détection d'interactions moléculaires dans des cellules utilisant une combinaison de promoteurs et de biocapteurs inductibles
CN101784895A (zh) 2007-06-26 2010-07-21 协乐民公司 预测肝细胞中生物学系统响应的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007136724A2 *

Also Published As

Publication number Publication date
US8597899B2 (en) 2013-12-03
JP2014029346A (ja) 2014-02-13
CA2652562C (fr) 2015-05-12
US20130190198A1 (en) 2013-07-25
WO2007136724A2 (fr) 2007-11-29
WO2007136724A3 (fr) 2008-03-13
US20140212892A1 (en) 2014-07-31
JP5888521B2 (ja) 2016-03-22
US20090298703A1 (en) 2009-12-03
JP2009537822A (ja) 2009-10-29
CN101484806A (zh) 2009-07-15
JP5406019B2 (ja) 2014-02-05
CA2652562A1 (fr) 2007-11-29
US8114615B2 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
US8114615B2 (en) Method for automated tissue analysis
Levsky et al. Fluorescence in situ hybridization: past, present and future
Price et al. Advances in molecular labeling, high throughput imaging and machine intelligence portend powerful functional cellular biochemistry tools
EP1984737A2 (fr) Procédé permettant de prédire les réponses des systèmes biologiques
Schubert et al. Next-generation biomarkers based on 100-parameter functional super-resolution microscopy TIS
EP2171443A1 (fr) Procédé de prédiction des réponses de systèmes biologiques dans des hépatocytes
Kwok et al. Multiplexed laser particles for spatially resolved single-cell analysis
Levenson et al. Multispectral imaging and pathology: seeing and doing more
Levenson et al. Modern Trends in Imaging X: Spectral Imaging in Preclinical Research and Clinical Pathology
Mignardi et al. Bridging histology and bioinformatics—computational analysis of spatially resolved transcriptomics
Tárnok et al. Cytomics–importance of multimodal analysis of cell function and proliferation in oncology
Levenson et al. Spectral imaging in preclinical research and clinical pathology
Lin et al. A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours
EP4109333B1 (fr) Procédé d'analyse d'échantillons biologiques
Pierzchalski et al. Introduction A: Recent advances in cytometry instrumentation, probes, and methods
WO2009015263A2 (fr) Procédés pour caractériser une proximité de cellule
Xiao et al. Pipeline for assessing tumor immune status using superplex immunostaining and spatial immune interaction analysis
Herrington Pathology and its role in medical science and practice
Novo et al. Single cell and population level analysis of HCA data
Bouzekri et al. A Computational Workflow for Cell Line Profiling by Imaging Mass Cytometry
Monk Faster, surer prediction: Harnessing automated microscopy for drug discovery
Patel et al. Next-gen disease profiling by integrating histopathology with spatial multi-omics data
Conroy et al. Developing a Comprehensive Taxonomy for Human Cell Types
Valet et al. Cytomics: From cell States to predictive medicine
Bratosin et al. NEW HORIZONS IN FLOW CYTOMETRY BY CYTOMICS AND BIOINFORMATICS. A MINIREVIEW.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081215

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20090526

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120226